Lantern Pharma opened lower at $0.47, compared with its previous close of $0.48. In the last trading session, the stock traded between $0.45 and $0.52. It showed a downward intraday trend.
An investment of $100 made 5 years ago in Lantern Pharma is now worth
$ 4.80
Resulting in a loss of
$ 95.20 (95.20%)
Note: Past profits do not guarantee future returns.
No analyst rating data available.
Today's Change
$-0.02 (-3.33%)
Day High
$0.52
Day Low
$0.45
Day Open
$0.47
Prev Close
$0.48
Volume
1,97,641
1W Return
-19.13%
1M Return
-36.21%
3M Return
-83.48%
6M Return
-77.75%
1Y Return
-86.86%
Market Cap ($ Mn)
7
PE Ratio
-
PB Ratio
-
PEG Ratio
-
ROE
-128.51%
ROCE
-131.60%
EPS (TTM)
$-0.55
1 Week
-19.13%
1 Month
-36.21%
3 Months
-83.48%
6 Months
-77.75%
9 Months
-83.68%
Lantern Pharma establishes LP-184 dosing for GBM trial
Recommended dose for expansion set at 0.39 mg/kg IV on days 1 and 8. Spironolactone combination projects 2- to 3-fold higher intratumoral exposure. PTGR1 biomarker threshold exceeded by 75% of available pretreatment samples. One patient remained stable for over 22 months post-enrollment despite no objective response.
2 days agoLantern Pharma closes $4M upfront in registered direct offering
Lantern Pharma closed a registered direct offering for 3,669,725 shares at $1.09 per share. Upfront gross proceeds total approximately $4 million before fees and expenses. Concurrent private placement includes warrants for up to another $4 million if exercised. Net proceeds are designated for working capital and general corporate purposes.
1mo agoLantern Pharma to detail OMAI agentic AI roadmap and economics
Lantern Pharma hosts webinar today detailing Open-Medicine AI's agentic platform roadmap. Market size estimated at $2.9 billion in 2026, projected to reach $13.8 billion by 2033. Session includes live demo of platform capabilities and discussion on subscription economics. Panna Sharma joined by Chief Scientific Officer and Principal Architect for the presentation.
1mo agoLantern Pharma secures US patent allowance for LP-284 blood cancer treatment
USPTO issued a Notice of Allowance for Lantern Pharma's patent application 18/500,032. Patent covers the use of drug candidate LP-284 for treating blood cancers. Claims specifically address mantle cell lymphoma (MCL) and double-hit lymphoma (DHL). Lantern Pharma is an AI-driven precision oncology company listed on NASDAQ.
1mo agoLantern Pharma Q2 EPS of $(0.57) misses estimate by 50%
Lantern Pharma's Q2 2026 EPS of $(0.57) missed analyst estimates of $(0.38) by 50%, driven by non-cash warrant expenses. However, the company achieved operational discipline, reducing its operating loss by 25% to $3.5 million through significant cuts in R&D spending. Strategic milestones included the spin-off of Open Medicine AI and progress in clinical trials for LP-300 and LP-184.
3mo agoLantern Pharma spins off Open-Medicine AI to scale drug discovery
Lantern Pharma Inc. formally establishes Open-Medicine AI as a separate corporate entity via board-approved licensing agreements. This strategic spin-off enables the AI platform to pursue independent funding and valuation, leveraging a new Bengaluru hub and targeting the growing $10 billion AI drug discovery market.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 5 years ago in Lantern Pharma is now worth
$ 4.80
Resulting in a loss of
$ 95.20 (95.20%)
Note: Past profits do not guarantee future returns.
